Summary Background Switzerland has made strides towards hepatitis C virus elimination, but as of 2019, elimination was not guaranteed. However, political interest in viral hepatitis has been increasing. We sought to develop a better understanding of Switzerland’s progress towards HCV elimination and the profile of remaining HCV-RNA-positive patients. Methods A previously described Markov model was […]
Summary As a result of epidemic levels of obesity and diabetes mellitus, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) will contribute to increases in the liver-related disease burden in Switzerland. A Markov model was built to quantify fibrosis progression among the NAFLD and NASH populations, and predict disease burden up to 2030. Long-term […]
Summary Background & Aims Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are increasingly a cause of cirrhosis and hepatocellular carcinoma globally. This burden is expected to increase as epidemics of obesity, diabetes and metabolic syndrome continue to grow. The goal of this analysis was to use a Markov model to forecast NAFLD disease […]
Résumé Contexte et objectifs En Suisse, la prévalence du virus de l’hépatite C (VHC) parmi les personnes qui s’injectent des drogues (UDI) est en baisse grâce aux efforts actifs de réduction des risques et au vieillissement de la population. Les avancées récentes dans le domaine thérapeutique du VHC pourraient offrir l’occasion d’orienter le traitement vers les populations à haut risque, dans le but de réduire la prévalence du VHC et de […]
Résumé Le virus de l’hépatite C (VHC) est un problème majeur de santé publique à l’échelle mondiale. On estime que 71 millions de personnes vivent avec une infection par le VHC et que la charge de morbidité liée à la cirrhose, au carcinome hépatocellulaire (CHC) et à la mortalité hépatique est en augmentation. L’avènement des thérapies antivirales à action directe (AAD) sans interféron, de courte durée (8 à 12 semaines), à haute efficacité, à excellente tolérance et faciles à […]
Summary Objective In Switzerland, fewer than 40% of hepatitis C virus (HCV) infected individuals have been diagnosed. The aim of this project was to analyse the distribution of HCV cases in order to develop better detection strategies. Study Design Historical data on the HCV-infected population in Switzerland were obtained from published literature, unpublished data and […]
Summary Background Chronic hepatitis C virus infection is a major cause of liver disease in Switzerland and carries a significant cost burden. Currently, only conservative strategies are in place to mitigate the burden of hepatitis C in Switzerland. This study expands on previously described modeling efforts to explore the impact of: no treatment, and treatment […]
Summary The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis […]
Summary The disease burden of hepatitis C virus (HCV) is expected to increase as the infected population ages. A modeling approach was used to estimate the total number of viremic infections, diagnosed, treated and new infections in 2013. In addition, the model was used to estimate the change in the total number of HCV infections, […]
Summary Chronic infection with hepatitis C virus (HCV) is a leading indicator for liver disease. New treatment options are becoming available, and there is a need to characterize the epidemiology and disease burden of HCV. Data for prevalence, viremia, genotype, diagnosis and treatment were obtained through literature searches and expert consensus for 16 countries. For […]
French 
English 
Spanish 
Russian 
Arabic